Meunier H, Labrie F
Can J Biochem Cell Biol. 1983 Jul;61(7):516-31. doi: 10.1139/o83-067.
In rat pars intermedia cells, the rate of alpha-melanocyte-stimulating hormone (alpha-MSH) secretion was so far known to result from a balance between the stimulatory effect of beta-adrenergic agonists and the inhibitory influence of dopaminergic substances. Recently, we have identified a second stimulatory substance, namely corticotropin-releasing factor (CRF). CRF is a potent stimulator of pars intermedia adenylate cyclase activity, cAMP accumulation and alpha-MSH release. A requirement for calcium ions was observed on basal as well as on CRF-induced alpha-MSH secretion. The beta-adrenergic and CRF effects on adenylate cyclase activity, as well as the dopamine inhibition of adenylate cyclase activity, are potentiated by guanine nucleotides (GTP). Stimulation of the beta-adrenergic receptor with isoproterenol causes a rapid loss in cAMP responsiveness, which can be completely blocked by beta-adrenergic antagonists and partially prevented by dopamine. These findings suggest that CRF should now be considered, in addition to beta-adrenergic agents, as a stimulator of the activity of pars intermedia cells and that cAMP is also involved as mediator of its action. Changes of receptor sensitivity, as well as interaction of the two stimulatory receptors with the inhibitory dopaminergic receptor, are involved in the fine control of pars intermedia cell activity. All three receptors appear to exert their action through a common pathway, namely changes of adenylate cyclase activity.
在大鼠垂体中间部细胞中,迄今为止已知α-黑素细胞刺激素(α-MSH)的分泌速率是由β-肾上腺素能激动剂的刺激作用与多巴胺能物质的抑制作用之间的平衡所决定的。最近,我们鉴定出了第二种刺激物质,即促肾上腺皮质激素释放因子(CRF)。CRF是垂体中间部腺苷酸环化酶活性、环磷酸腺苷(cAMP)积累和α-MSH释放的有效刺激物。在基础状态以及CRF诱导的α-MSH分泌过程中均观察到对钙离子的需求。鸟嘌呤核苷酸(GTP)可增强β-肾上腺素能和CRF对腺苷酸环化酶活性的作用,以及多巴胺对腺苷酸环化酶活性的抑制作用。用异丙肾上腺素刺激β-肾上腺素能受体会导致cAMP反应性迅速丧失,这可被β-肾上腺素能拮抗剂完全阻断,多巴胺可部分预防这种情况。这些发现表明,除了β-肾上腺素能药物外,现在还应将CRF视为垂体中间部细胞活性的刺激物,并且cAMP也作为其作用的介质参与其中。受体敏感性的变化,以及两种刺激受体与抑制性多巴胺能受体之间的相互作用,都参与了垂体中间部细胞活性的精细调控。所有这三种受体似乎都通过一条共同途径发挥作用,即腺苷酸环化酶活性的变化。